Fast Track Your 2025 Drug Development Program
Get a Head Start on Your Preclinical Studies
With four strategically placed preclinical research facilities throughout North America, we can get your investigational new drug (IND) and clinical trial application (CTA) studies underway in 8-10 weeks!
We offer a full range of in vivo non-GLP and GLP preclinical studies in both rodent and non-rodent species, to assess the safety of your small and large molecules in support of upcoming first-in-human clinical trials.
Our IND/CTA-enabling studies include:
- lead optimization
- preclinical pharmacology
- dose range finding
- pivotal toxicology (acute, sub-chronic, chronic, carcinogenicity)
- safety pharmacology
Time is of the essence―let’s get started!
Related resources that may interest you:
- eBook: Nonclinical Safety Testing Guide
- Webinar: Selecting the Right Species for Your Toxicology Program
- Scientific Journal: Achieving Optimal Preclinical Formulation and Drug Product Manufacture